Sobi is an international rare disease company dedicated to providing access to innovative treatments that make a significant difference for people with rare diseases.
Strong and growing portfolio
They have two business areas: Haemophilia and Specialty Care. Their research and product portfolio is primarily focused on haemophilia, inflammation, and genetic and metabolic diseases. In Haemophilia, they aim to take a leadership position in Europe, the Middle East and Africa. In Specialty Care, they provide treatments for rare diseases and specialty indications. Their experience and competence in rare disease and niche indications offers a platform from which they will continue to grow and provide continued and greater access to treatments for patients.
Integrated biotechnology company
Sobi is an integrated biotechnology company with in-house capabilities that encompass the entire value chain, from research, to preclinical and clinical development, biologics manufacturing and supply, to patient access and distribution. This integrated approach is a prerequisite for providing proprietary drugs, and an enabler for partnerships, especially at early stages of drug development.
With their dedication and strong capabilities across the entire value chain, they aim to become the preferred partner for pharmaceutical companies with strong franchises and promising drug candidates in rare disease and niche indications.
Growing international presence
With their head office in Stockholm, Sweden, the Sobi organisation spans 25 countries, delivering treatments to patients in over 60 countries across the globe. Europe is the core market for the haemophilia franchise. They aim to expand their business further.
Where is Swedish Orphan Biovitrum (SOBI)